Nov 6, 2019- Discovery marks the first time a new subtype of HIV-1 has been identified since 2000- Abbott is making this new strain accessible to the research community to evaluate its impact to diagnostic testing, treatments and potential vaccines-
Oct 22, 2019- One-third of Americans have heard someone say: "I drive better when I've smoked marijuana"- While drunk driving is on the decline, drug-impaired driving is on the rise[1]- Eleven states and Washington, DC, have legalized marijuana for recreational use; Illinois, Michigan are two of the next states to begin adult-use sales in 2020
- Oct 15, 2019- Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes
-
Oct 15, 2019-- Oct. 17, 2019, marks the one-year anniversary of legalized recreational cannabis nationwide-- A year after legalization, 71% of Canadians are concerned about its impact on road safety-- Survey shows Canadians want more to be done to keep roads safe
Oct 14, 2019- Collaboration combines Abbott′s world-leading glucose sensing technology with Omada Health's best-in-class, proprietary digital coaching platform to provide personalized, on-the-go care- As part of Omada's expanded Type 2 diabetes offering, FreeStyle Libre will be the exclusive CGM delivered directly to participants' doorsteps - expanding access to the technology for more people with diabetes- Sep 26, 2019- Proclaim™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*- More than 50 million people in the United States are affected by chronic pain- Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging
- Sep 25, 2019Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women
- Sep 16, 2019- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin- Two world leaders in diabetes work together to drive meaningful change in care
- Sep 10, 2019- New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis- This technology is the first machine learning developed algorithm that combines high sensitive troponin testing with other patient details to help doctors better determine if a heart attack is occurring
- Aug 26, 2019- The TRACK-TBI study found that 64% of people with the highest levels of a protein in the blood were confirmed to have brain injury through an MRI scan, even when a CT scan did not detect it- Abbott's diagnostic test, currently in development, is poised to be the first point-of-care blood test for assessing concussions on its next generation i-STAT™ device, providing doctors results in 15 minutes
- Aug 14, 2019- Agreement gives law enforcement access to the most advanced handheld tools to help detect drug and alcohol-impaired drivers- Collaboration is a major step in keeping roads safer as recreational marijuana legalization accelerates[1]
- Jul 15, 2019- U.S. approval for MitraClip G4 offers a next-generation approach to mitral valve repair- G4 includes new clip sizes and an enhanced leaflet grasping feature
- May 21, 2019- Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR- Data suggest the first-of-its-kind device reduces difficult-to-treat tricuspid regurgitation at 30 days- Study builds upon Abbott's success with its proven MitraClip™ clip-based technology in treating a similar disease on the left side of the heart
- May 14, 2019- Partnership with NIH aims to increase understanding and accelerate the application of neurostimulation therapies- The BRAIN Initiative brings together the brightest minds across disciplines to improve the treatment and prevention of brain disorders
- Apr 29, 2019- Research found Abbott's High-Sensitive Troponin-I blood test may identify adults at risk of having a cardiac event, independent of other heart disease risk factors- Abbott's core laboratory diagnostic test is the first troponin blood test with CE Mark that can more accurately predict risk of developing heart disease, when added to other heart disease risk assessments, than using other assessments alone
- Mar 14, 2019- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation- Approval is based on groundbreaking pivotal data from the COAPT™ Trial- New indication significantly expands number of people with mitral regurgitation that can be treated with the MitraClip device
- Feb 20, 2019Collaboration will enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible(i) with FreeStyle Libre portfolio of products
- Jan 21, 2019With approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation
-
Jan 19, 2019- Data from two recent studies presented at NANS 2019 demonstrate key benefits of BurstDR™ stimulation- Microdosing BurstDR stimulation at lowest effective energy allows patients to manage their pain without the burden of recharging their devices- Additional data further showed switching from other types of SCS therapies to Abbott’s BurstDR stimulation significantly reduced pain and the need for opioid medication
-
Nov 15, 2018New White Paper Shares Research Findings on Perceptions and Awareness of Medical Device Cybersecurity, Need for Collaboration to Address Cybersecurity Challenges
-
Oct 25, 2018NEW ASSAYS EMPOWER CLINICIANS TO MORE QUICKLY MAKE THE RIGHT DIAGNOSIS AT THE POINT-OF-CARE AND PRESCRIBE THE RIGHT TREATMENT
-
Oct 17, 2018PRELIMINARY RESEARCH INDICATES THAT A DIAGNOSTIC TEST CURRENTLY IN DEVELOPMENT, THAT IS DONE AT THE PATIENT'S SIDE IN MINUTES, HAS SIMILAR ACCURACY TO A HIGH-SENSITIVE TROPONIN TEST FOR EARLY RULE OUT OF A HEART ATTACK
-
May 22, 2018- Data presented at EuroPCR indicated excellent clinical outcomes for Portico in a real-world setting to treat common and life-threatening heart valve disease with minimally invasive option- Portico is the first fully resheathable, repositionable and retrievable device – now with a sheathless delivery option – to replace a diseased or damaged aortic heart valve without major surgery- Data are consistent with earlier study results used to support CE Mark
-
Apr 11, 2018- Largest-ever randomized trial to evaluate superiority of light-based, three-dimensional imaging (optical coherence tomography (OCT)) versus X-ray-based angiography in patients with complex coronary artery disease who receive a stent- Trial will assess if stent procedures guided by high-resolution imaging result in larger vessel diameters and improved patient clinical outcomes versus stent procedures that use standard-of-care imaging- Use of OCT imaging may help doctors be more precise in stent implantation
- Mar 6, 2018- First and only pediatric mechanical heart valve developed to include newborns and infants- Life-saving technology - the size of a dime - provides new treatment option to address unmet need- Nearly one in four children with critical heart defects may require surgery or other procedures in their first year of life[1]
-
Oct 11, 2017- A new dataset published in The Lancet: Psychiatry highlights the largest prospective study in DBS for chronic, treatment-resistant depression
- Jan 10, 2017- Innovative solution designed for blood and plasma screening maintains highest levels of accuracy while substantially increasing productivity
- Jan 10, 2017- Next generation of harmonized systems, combined with recently launched AlinIQ professional services, provide a unique solution to help labs and hospital systems achieve measurably better healthcare performance- The Alinity family delivers unprecedented integration in diagnostic testing to help solve the lab's most pressing challenges- New clinical chemistry and immunoassay technologies allow for cost-effective volume growth in a footprint half the size of Abbott's current diagnostic systems[1]- Error-proof design elements help prevent costly mistakes in the lab- Easy-to-use software, common across all Alinity systems, helps labs simplify training and manage strained staffing resources- Scalable system design enables labs to address current and future needs
